Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 222144

AbstractCase ReportDiscussionConclusionAcknowledgementReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"

Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018

Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."

Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018

Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."

Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018

Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."

Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
On Sep 2018

Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."

Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata

Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
On Aug 2018

Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".

Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
On Aug 2018

Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".

Dr. Mamta Gupta
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018

Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.

Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."

Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
On May 11,2011

Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."

Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
On April 2011

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.

Dr. Anuradha
On Jan 2020

Important Notice

Original article / research
Year : 2022 | Month : September | Volume : 16 | Issue : 9 | Page : ED01 - ED03 Full Version

COVID-19 Infection in a Sickle Cell Anaemia Patient from Sudan

Published: September 1, 2022 | DOI:
Abdel Rahim Mahmoud Muddathir

S1. Associate Professor, Department of Medical Laboratory Technology, Taibah University, Madina, Saudi Arabia

Correspondence Address :
Dr. Abdel Rahim Mahmoud Muddathir,
Associate Professor, Department of Medical Laboratory Technology,
Taibah University, Madina, Saudi Arabia.


Sickle Cell Disease (SCD) is an inherited disorder with variable clinical presentation and low immunity. Coronavirus Disease-2019 (COVID-19) is a pandemic disease with a high-risk in chronic disease patients and older adults. SCD is widely distributed in Sudan; many SCD patients are infected with COVID-19. Despite this, no published data is available. This case report demonstrated the haematological and clinical course of a Sudanese sickle cell anaemia patient with COVID-19. A 20-year-old male patient was admitted to a hospital for 15 days. Demographic and clinical data were obtained from his medical records. A blood sample was taken at the time of admission and during hospitalisation. Tests were performed during admission, including Complete Blood Count (CBC), liver function test, renal function test, coagulation studies, viral screening, and urine general. The patient was diagnosed with COVID-19 using the Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) test based on the nasopharyngeal swab and COVID-19 IgG and IgM using Enzyme Linked Immunosorbent Assay (ELISA) for the previous infection. The patient received intravenous fluids, antibiotics, analgesia, oxygen supplementation, and blood transfusion two times during hospitalisation, and there was no need for Intensive Care Unit (ICU) admission. The patient’s prognosis was good; he was discharged on day 16 with no symptoms and a negative result of the COVID-19 PCR test. A severe illness was expected because he was infected twice by COVID-19, the patient showed mild clinical symptoms with a good prognosis, so further studies are required to understand COVID-19 among Sudanese SCD patients.


Coronavirus disease, Complete blood count, Haemoglobin S

Case Report

A 20-year-old male reported with a chief complaint of fever, cough, and joint pain for two days. He was diagnosed with homozygous SCD two years back. He was regularly taking 5 mg of folic acid each day. He had a history of hospital admission due to painful Vaso-Occlusive Crisis (VOC) and Acute Chest Syndrome (ACS) for three-five days. He had auto-splenectomy and cholecystectomy at 13 and started taking hydroxyurea three times a week.

On day one, an investigation was performed at the hospital, including the following: Complete Blood Counts (CBC), liver function test, renal function test, and urine general. Laboratory test data included a white blood cell count of 12.99×109/μL, Hb 7.7 g/dL, HCT 18.5%, platelets 220×109 cells/mm3 with normal renal and liver function tests, and clear urine analysis. Screening tests for HBsAg, HCV, and HIV were negative.

On day two, no investigation was requested, and the patient suffered from high body temperature (37.8°C) and generalised pain. He was under treatment of ceftriaxone intravenously every 12 hours for five days. Also, he took a 500 mg paracetamol tab every six hours.

On day three, he presented a SpO2 of 86% and a temperature of 39°C. Supplemental oxygen was indicated, and he also lost both senses of smell and taste. Hence, the physician requested a nasopharyngeal swab for Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2). He also said he suffered from the same symptoms with cough and generalised pain six months ago. He did not make an investigation for COVID-19 at that time. He isolated himself at home for two weeks, took pain relievers, and did not required hospital, so COVID IgG and IgM were requested. Clinical examination showed mild hepatomegaly. The laboratory investigations asked on day three included CBC, liver profile, renal profile, C reactive protein, lactate dehydrogenase, ferritin level, and coagulation study, as shown in (Table/Fig 1), (Table/Fig 2). The laboratory investigation of the patients started to show signs of haemolysis. His haemoglobin was reduced to 2.45 g/dL, LDH level was increased from 345 to 726 U/L, and total bilirubin was raised from 2.7 to 4.3 g/dL. Also, signs of inflammation began, and his white blood cell count was 14000 cells/μL. CRP increased from 32.42 to 66.95 mg/dL, and serum ferritin was increased from 934 to 2730.4 mg/mL. Ceftriaxone and clarithromycin were given one tablet of 500 mg every 12 hours for five days.

On day 4 COVID-19 was confirmed and also there was a previous infection with COVID-19 (COVID IgG = 3.981 AU/mL [NR:0-1 AU/mL] and COVID IgM = 1.275 AU/mL [NR:0-1 AU/mL]). The coagulation study showed prolonged prothrombin time (22.9 seconds with INR 1.67), normal Activated Partial thromboplastin time, and normal TT (thrombin time). He was given heparin therapy and received two bags of whole blood transfusion, by which his haemoglobin was increased from 2.45 to 8.18 g/dL. After a blood transfusion, joint pain, dyspnoea, and haemolysis were improved. The radiographic findings showed mild cardiomegaly due to chronic anaemia; and hepatomegaly. Chest radiography was normal. He was given 500 mg vitamin C, 30 mg zinc, and 500 mg paracetamol tablets.

He stopped Oxygen supply after day seven, but the fever was continuous until day 14. He was treated with 500 mg of paracetamol twice every six hours and 500 mg of azithromycin for three days. His laboratory exams were stable, a nasopharyngeal swab for SARS-CoV-2 on day 15 was negative, and he was discharged on day 16. His haemoglobin level was 7.25 g/dL, and oxygen saturation 96% without any symptoms during discharge. One month after hospitalisation, the patient was cleared of COVID-19. His physical examination and laboratory tests were normal according to his health situation as a Sickler patient, and his haemoglobin was improved.

The patient gave written informed consent to participate in the study and to publish his clinical data.


COVID-19 (caused by SARS-CoV-2) is a pandemic viral infection disease discovered in Wuhan, China, and rapidly spread worldwide (1). Patients infected with COVID-19 suffer from various mild to severe clinical symptoms, including fever, cough, fatigue and gastrointestinal symptoms, pneumonia, acute respiratory syndrome, acute respiratory failures, sepsis, and septic shock (2). Patients with chronic diseases such as cardiovascular diseases, diabetes, respiratory diseases, chronic kidney disease, and obesity were at high-risk of developing severe COVID-19 with a bad prognosis (3).

Patients with SCD, on the other hand, are considered to be particularly at risk of COVID-19 complications by the Thalassaemia International Federation (TIF) due to a number of factors, including COVID pneumonia which can lead to acute chest syndrome, which is a significant cause of morbidity and mortality in SCD patients due to the low immunity of those patients. Medical care for sickle cell anaemia and COVID-19 infection is a difficult task (4).

SCD is widely distributed in Africa. In Sudan, SCD has a high prevalence in Western Sudan. In the Messeryia tribe, one out of every 123 children is at risk of developing SCD (5).

The outbreak of COVID-19 infected many people, including SCD patients. Many studies on sickle cell patients with COVID-19 showed mild to moderate clinical course. In the USA, four sickle cell patients with COVID-19 showed a mild clinical course with no deaths (6). In the UK, the authors reported only one death in 10 SCD patients infected with COVID-19. Five patients had mild symptoms without hospitalisation and the remaining recovered after a short period of hospitalisation (7). The French national consortium found that the clinical outcome of COVID-19 was mild in patients with SCD, especially those younger than 45 years (8).

Although Sudan had a high prevalence of SCD and COVID-19 was widespread, the haematological and clinical outcome of those patients with COVID-19 is unknown. On the other hand, there was no obvious treatment guideline for sickle cell patients with COVID-19 in Sudan. The SCD patients are treated like any patient affected with COVID-19. They are managed with painkillers such as acetaminophen and morphine in addition to intravenous antibiotics (ceftriaxone), and oral azithromycin with vitamin support like Vitamin D, C, and zinc. This case report aimed to illustrate the clinical outcome in Sudanese SCD patients with COVID-19 to put a protocol for managing and treating this condition.

The patient’s age was 20, the most affected age group, as shown in a previous study by Arlet JB et al., (8) and Ramachandran P et al., (9). The studied patient was affected by COVID-19 two times. He presented with cough and pain the first time, with loss of smell and taste. He did required hospitalisation and recovered after isolating himself at home for two weeks.

Previous literature shows that patients may have reinfection by COVID-19 due to low lymphopenia (10),(11). The patient was infected for the second time, but unfortunately, no investigation was recorded after the first infection to confirm the previous issue. He presented with joint pain, fever, cough, and loss of sensation, and he needed oxygen supplementation for the second time. This case was in accordance with Al-Ansari RY et al., who reported that all patients presented with bone pain, cough, and fever in 80%, 40%, and 40% of cases, respectively (12).

The patient received no support in the ICU, similar to that reported by Hejlbronner C et al., (13) and Beerkens F et al., (14). This indicates a milder clinical presentation of SCD with COVID-19 than previously predicted.

Arlet JB et al., reported that most sickle patients with COVID-19 infection required blood transfusion before or during admission to ICU (8). The studied patient received two whole blood bags, indicating that the blood was diluted because of the patient’s enormous intravenous fluid intake to lower his fever. The laboratory investigation of the patient had been improved with clinical enhancement; these findings were similar to Beerkens F et al., findings (14). Despite the deviation of the haematological findings from the normal range (High white blood cells, low red blood cells, Haemoglobin, and haematocrit) and also the biochemical lab tests (High total Bilirubin, Direct Bilirubin, Aspartate transaminase, C-reactive protein, and, lactate dehydrogenase level) the patient has been discharged from the hospital by the physician in charge. Because he was anaemic before as SCD patient, the Hb, RBCs, and HCT are usually low in these patients. Also, SCD patients develop haemolytic jaundice (High total Bilirubin, Direct Bilirubin) due to red cell destruction during the crisis. Also, because of infection, the inflammatory markers like C-reactive protein, LDH, and ferritin need time to get dropped down, as mentioned by his physician. According to that, patient health was not affected by the discharge.

The study patient gives good responses to medication with stable health status. The finding of this case study did not identify SCD as a risk factor for COVID 19, as shown by Abdulrahman A et al., (15). The reported case study did not differ from previous cases regarding hospitalisation time and clinical outcome. The patient presented with an excellent response to medication and stable health status.


In conclusion, the case report shows that SCD patients with COVID-19 have a favourable clinical outcome and a good prognosis. Sickle cell patients need special care, particularly among the pandemic COVID-19. Therefore, clinicians should pay attention to the SCD patients’, and a treatment protocol should be established for good prognosis and better patient management. Further studies with a large sample size will be needed to understand COVID-19 in SCD patients better.


Many thanks to Dr. Ream Elzain Abdelgadir for her valuable comments and assistance.


Zheng J. SARS-CoV-2: An emerging coronavirus that causes a global threat. Int J Biol Sci. 2020;16(10):1678-85. Doi: PMID: 32226285. [crossref] [PubMed]
Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: A comprehensive review. J Intern Med. 2020;288(2):192-206. Doi: PMID: 32348588. [crossref] [PubMed]
Guan WJ, Liang WH, Zhao Y. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur. Respir. J. 2020;55(5):2000547. Doi: PMID:32341104. [crossref] [PubMed]
Thalassemia International Federation. The COVID-19 pandemic and hemoglobin disorders: A contribution of thalassemia international federation to its global Patients’ community (version III, updated). Thalassemia International Federation. 2020.
Sabahelzain MM, Hamamy H. The ethnic distribution of sickle cell disease in Sudan. Pan Afr Med J. 2014.18:13. Doi: 10.11604/pamj.2014.18.13.3280. PMID: 25360197. [crossref] [PubMed]
Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020;189(5):851-52. Doi: PMID: 32314798. [crossref] [PubMed]
Chakravorty S, Padmore-Payne G, Ike F, Tshibangu V, Graham C, Rees D, et al. COVID-19 in patients with sickle cell disease- A case series from a UK Tertiary Hospital. Haematologica. 2020;105(11):2691-93. Doi: PMID: 33131264. [crossref] [PubMed]
Arlet JB, de Luna G, Khimoud D, Odievre MH, de Montalembert M, Joseph L, et al. Prognosis of patients with sickle cell disease and COVID-19: A French experience. Lancet Haematol. 2020;7(9):e632-34. Erratum in: Lancet Haematol. 2020;7(9):e635. Doi: [crossref]
Ramachandran P, Perisetti A, Kathirvelu B, Gajendran M, Ghanta S, Onukogu I, et al. Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience. eJHaem. 2020;1:608-14. Doi: PMID: 35845018. [crossref] [PubMed]
Alberca RW, Yendo TM, Leuzzi Ramos YÁ, Fernandes IG, Oliveira LM, Teixeira FM, et al. Case Report: COVID 19 and chagas disease in two coinfected patients. Am J Trop Med Hyg. 2020;103(6):2353 56. Doi: PMID: 33025877. [crossref] [PubMed]
Netea MG, Giamarellos Bourboulis EJ, Dominguez Andres J, Curtis N, van Crevel R, van de Veerdonk FL, et al. Trained immunity: A tool for reducing susceptibility to and the severity of SARS CoV 2 infection. Cell. 2020;181:969 77. Doi: PMID: 32437659. [crossref] [PubMed]
Al-Ansari RY, Abdalla LM, Qomawi YA, Alromaih LJ, Bakkar MO, Shilash AS, et al. Coronavirus disease 2019 (COVID-19) in special groups: A single center experience in sickle cell disease patients in Saudi Arabia. J Family Community Med. 2022;29(1):71-78. Doi: 10.4103/jfcm.jfcm_376_21. Epub 2022 Jan 19. PMID: 35197731.
Heilbronner C, Berteloot L, Tremolieres P, Dupic L, de Saint Blanquat L, Lesage F, et al. Patients with sickle cell diseaseand suspected COVID-19 in a pediatric intensive care unit. Br J Haematol. 2020;190(1):e21-24. Doi: PMID: 32420608. [crossref] [PubMed]
Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020;95(7):E154-E156. Doi: 10.1002/ajh.25809. Epub 2020 Apr 21. PMID: 32243621. [crossref] [PubMed]
Abdulrahman A, Wael M, AlAmmadi F, Almosawi Z, Alsherooqi R, Abduljalil M, et al. Is sickle cell disease a risk factor for severe COVID 19 outcomes in hospitalized patients? A multicenter national retrospective cohort study. eJHaem. 2021;2(2):167 74. Doi: PMID:33821258. [crossref] [PubMed]

DOI and Others

DOI: 10.7860/JCDR/2022/56403.16888

Date of Submission: Mar 16, 2022
Date of Peer Review: Apr 23, 2022
Date of Acceptance: Jul 25, 2022
Date of Publishing: Sep 01, 2022

• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. Yes

• Plagiarism X-checker: Mar 25, 2022
• Manual Googling: Jul 21, 2022
• iThenticate Software: Aug 09, 2022 (5%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)